Anavip

Anavip
Clinical data
Trade namesAnavip
Other names
  • Crotalidae immune F(ab')2 (equine)
  • Viper antivenom
AHFS/Drugs.comMonograph
Legal status
Legal status
Identifiers
PubChem SID
DrugBank
UNII

Anavip is the brand name of a snake antivenin indicated for the management of people with North American rattlesnake envenomation.[3][4][1] As defined by the US Food and Drug Administration (FDA), the proper name is crotalidae immune F(ab')2 (equine).[2] It is manufactured by Rare Disease Therapeutics.

Anavip is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus. The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2.[1]

References

  1. 1 2 3 "Anavip crotalidae immune F(ab')2 (equine) Lyophilized Powder for Solution for Injection For Intravenous Use Only" (PDF). Rare Disease Therapeutics. Retrieved 18 August 2020.
  2. 1 2 "Anavip". U.S. Food and Drug Administration (FDA). 1 April 2021. STN: 125488. Retrieved 3 October 2025.
  3. ↑ Cocchio C, Johnson J, Clifton S (January 2020). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. PMID 31974558.
  4. ↑ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.


This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.